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BACKGROUND
The Ministry of Health and Long-Term Care (MOHLTC) has supported prenatal genetic
screening in Ontario since 1993, publically funding an array of screening options. In February
2013, a new screening option became available in Ontario. This technology, known as noninvasive prenatal testing (NIPT), promises improved accuracy and safety and is currently only
available to those willing to independently pay for the test (Okun, Teitelbaum, Huang, Dewa, &
Hoch, 2014). With increasing public interest in the technology and wanting to maintain a
centralized, standardized, high quality provincial screening program, the Ministry has
recognized the need for an urgent response on the use of NIPT within the public system. In
March 2014, the Ministry appointed a Prenatal Genetic Screening Group (PGSG) to advise on
current screening practices and make recommendations for an improved prenatal genetic
screening program in Ontario. As part of the group’s work, the Ministry has requested an
economic evaluation, examining the costs and performance outcomes associated with NIPT
and its introduction into the public system.
INTRODUCTION TO PRENATAL GENETIC SCREENING
Prenatal genetic screening for fetal chromosomal abnormalities began in the mid-1960s. At this
time the screening involved offering women who were considered of advanced maternal age
(>35 years of age at expected date of delivery) an invasive test called an amniocentesis. This
test carried with it a small risk of fetal loss (0.01% to 0.5%). The age 35 was chosen as it was
the determined point where the risk of fetal loss related to screening was less than the chance
of identifying a significant fetal chromosomal condition (Prenatal Screening Ontario, 2014).
Since this time, great advances in prenatal genetic technology have been made, lessening the
need for invasive testing and subsequently reducing the number of fetal losses due to
complications. Today, prenatal genetic screening consists of minimally invasive procedures
such as blood work and ultrasounds and has become a routine part of publicly funded prenatal
care for all women in Ontario.
Women may choose to have screening done if they wish to learn more about their pregnancy,
want to gather the best information and prepare for their newborn and the delivery, or want the
opportunity to terminate a pregnancy if a diagnosis is made. Prenatal genetic screening does
not screen for all chromosomal abnormalities nor does it provide a definitive diagnosis. Women
who receive a positive screen are given the option of further diagnostic testing. This consists of
either chorionic villus sampling (CVS) or amniocentesis. Both procedures carry a small risk of
fetal loss (1% and 0.01% to 0.5% respectively; Prenatal Screening Ontario, 2014).
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With the discovery of cell-free fetal DNA (cffDNA) in maternal blood, a new form of screening
has evolved. This screening is referred to as non-invasive prenatal testing (NIPT) and offers an
improved detection rate (DR) and fewer false positives. This test has the potential to further
reduce the number of invasive tests performed, subsequently reducing the number of fetal
losses due to complications (Langois & Brock, 2013).
FETAL CHROMOSOMAL CONDITIONS
Typically, individuals have 46 chromosomes or 23 pairs of chromosomes in each cell of their
body. This is the result of proper chromosome alignment during the creation of an egg or a
sperm. If the chromosomes do not properly align during this process, too few or too many
chromosomes can result. This is referred to as aneuploidy and once this occurs the
chromosome imbalance will be in every cell and cannot be treated. The cause of this
misalignment is unknown; however, it is known that it occurs more often as women age. The
misbalance of chromosomes can lead to development and growth challenges in the fetus, often
resulting in spontaneous miscarriage (Prenatal Screening Ontario, 2014). The incidence of any
fetal chromosomal condition is approximately 1 in 160 live births, with the majority of these
being aneuploidies (Canadian Agency for Drugs and Technologies in Health, 2014). The most
common fetal aneuploidies include Trisomy 21 (Down syndrome) and Trisomy 18 (Edward
syndrome). Prenatal genetic screening assesses the chance of carrying a fetus with one of
these conditions, along with assessing for open neural tube defects (ONTDs) and other
structural chromosomal conditions.
Down syndrome (Trisomy 21)
Down syndrome is the most common aneuploidy, occurring in about 1 in 1000 births
in Ontario (Prenatal Screening Ontario, 2014). This rate varies with age, being more
common as women age. The common characteristic shared by those with Down
syndrome is extra genetic material associated with chromosome 21. The effects
associated with the extra genetic material are highly variable among individuals.
Individuals with Down syndrome may be predisposed to certain medical and
learning-style challenges. Common medical conditions associated with Down
syndrome include heart, stomach, thyroid, hearing, and vision problems. Each
individual with Down syndrome is different and there is no way to predict the level of
disability during pregnancy. There is no cure for Down syndrome, but early
intervention and medical management can improve the common conditions
associated with it (Canadian Down Syndrome Society, 2009).
Edward syndrome (Trisomy 18)
Edward syndrome is less common than Down syndrome, occurring in about 1 in
6,000 births. This condition also varies with age, being more common as women
age. Individuals with Edward syndrome have extra genetic material associated with
chromosome 18 and are predisposed to serious congenital malformations. Of the
pregnancies diagnosed, 95% will result in a miscarriage and of the babies born,
95% will die within the first year of life (Prenatal Screening Ontario, 2014).
Open Neural Tube Defects (ONTDs)
ONTDs occur when the spine or brain does not develop properly during the first
trimester. During this time the neural tube folds together; if complete closure or
folding of the tube does not occur, an opening remains. Depending on the location
of this opening, the type and severity of ONTD varies. An opening lower in the spine
is called spina bifida, which can lead to physical and intellectual disabilities. An
opening higher in the spine is called anencephaly, which is considered incompatible
12
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with life. The incidence of ONTDs in Canada is 1 in 2,000 births (Prenatal Screening
Ontario, 2014).
CURRENT SCREENING SYSTEM
Clinical practice guidelines indicate that all pregnant women in Canada should be offered the
option of prenatal genetic screening. This should be done through an informed counseling
process, where non-directive information is provided and client decisions are respected
(Chitayat, Langois, & Wilson, 2011). In Ontario, four different screening tests are available,
three if the client presents before 14 weeks gestation and one if the client presents after 14
weeks (Prenatal Screening Ontario, 2014). All options involve the measurement of maternal
serum biomarkers through a maternal blood sample. This may be accompanied by a second
maternal serum sample and/or a nuchal translucency (NT) ultrasound.1 The level of accuracy of
each test varies, with each screen carrying a different detection rate (DR) and false positive rate
(FPR). Screens that have a higher DR (proportion of those with the condition with a screen
positive result) and a lower FPR (proportion of those without the condition with a screen positive
result) are considered superior. The Society of Obstetricians and Gynecologists Canada
(SOGC) recommends that the minimum standard of any prenatal screen for Down syndrome
offered in Canada should be a DR of 75% and a FPR no greater than 3-5% (Chitayat et. al.,
2011). The overall accuracy of the four tests currently offered in Ontario ranges from a DR of
75% - 90% and a FPR of 2% - 10% (Prenatal Screening Ontario, 2014; see Exhibit 1).
The current available screening options that may be offered and are publically funded include:







Integrated Prenatal Genetic Screening (IPS): Has the highest DR and lowest FPR. It
involves two maternal serum samples, one in the first trimester (before 14 weeks
gestation) and one in the second trimester (after 14 weeks gestation). It also involves an
NT ultrasound. Due to its superior accuracy, the majority of women in Ontario undergo
this screen (Okun et al., 2014).
First Trimester Screening (FTS): This screen provides the earliest results (first
trimester). It involves one maternal serum sample and a NT ultrasound. It has a lower
DR and higher FPR than IPS.
Serum Integrated Prenatal Screening (SIPS): This test requires two maternal serum
samples, one in the first trimester and one in the second. Few women (2%) in Ontario
undergo this screen (Okun et al., 2014), as it does not involve NT ultrasound. This test is
mainly used in geographical areas where first trimester ultrasound is not available
(Chitayat et. al., 2011).
Maternal Serum Screen (Quad screening): This is a second trimester screen (only
screen offered to those over 14 weeks gestation) that involves taking one maternal
serum sample. This screen has the highest FPR.

Overall, the uptake rate of screening in Ontario is estimated to be 67% (Okun et al., 2014). The
type of screen offered and chosen may depend on geographical location, gestational age, and
provider and client preference. In addition to one of the above screens, all pregnant women
should be offered a detailed second trimester ultrasound (between 18 and 20 weeks gestation).
This ultrasound screens for anatomic abnormalities, including ONTDs, and can be used to
modify the known chance of aneuploidy established by prior screening (Chitayat et. al., 2011).
1

NT ultrasound is done between 11 and 13 weeks gestation. It measures the thickness of tissue on the back of the
fetus’s neck, which can be indicative of certain chromosomal conditions. Its use is recommended by the International
Society of Prenatal Diagnosis; however, its use depends on geographical location, as some areas within the province
do not have access to first trimester scanning expertise.
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If a client receives a screen positive on any of these tests, it indicates that the chance of a fetal
chromosomal condition or ONTD is higher than the specified cut-off. It does not necessarily
mean that the fetus has one of these conditions. The majority of screen positives will be false
positives (meaning the fetus does not actually have the condition); however, there is no way of
knowing this until the baby is born or diagnostic testing is performed (Prenatal Screening
Ontario, 2014). It is estimated that approximately 60% of screen positive women and 1.2% of
screen negative women will choose to undergo diagnostic testing (Okun et al., 2014).
Diagnostic Testing
Diagnostic tests are invasive tests that are highly accurate at detecting fetal
chromosomal conditions. Clinical practice guidelines indicate that clients who have a
screen positive may be eligible for diagnostic testing if they are 35 years of age or
older, have a family history of genetic chromosomal conditions, conceived through
IVF with intracytoplasmic sperm injection, or have certain ultrasound findings
(Prenatal Screening Ontario, 2014; Ministry of Health and Long Term Care, 2012).
Two forms of testing exist: amniocentesis and CVS. CVS involves the removal of
placental cells in order to analyze fetal genetic material. This procedure is
performed between 11 and 13 weeks gestation. It carries a fetal loss risk of 1% and
does not test for ONTDs (Prenatal Screening Ontario, 2014). The majority of women
do not receive screening results in time for CVS and therefore their only option is
amniocentesis (Okun et al., 2014). Amniocentesis is performed between 15 and 22
weeks gestation and involves the removal of amniotic fluid to analyze fetal genetic
material. This test carries a slightly lower fetal loss risk (0.01% - 0.5%, Prenatal
Screening Ontario, 2014); however, because the procedure occurs at a later
gestational age, women may experience increased anxiety and may be at higher
risk of complications if choosing to terminate (Vanstone, King, deVrijier, & Nisker,
2014).
NEW DEVELOPMENTS IN PRENATAL GENETIC SCREENING
Advances in technology have led to the development of a new type of prenatal genetic
screening. This technology is known as non-invasive prenatal testing (NIPT) and offers the
promise of improved accuracy and safety2 in the screening of Down syndrome. Just like current
screening approaches, NIPT involves the analysis of a maternal blood sample. However,
instead of analyzing maternal biomarkers (as current approaches do), NIPT analyzes fetal DNA
found in maternal blood. This DNA is known as cell-free fetal DNA (cffDNA) and it makes up 1020% of the maternal plasma (Langois & Brock, 2013). With advanced technology, this DNA can
be sequenced and analyzed for certain fetal chromosomal conditions. cffDNA can be detected
and analyzed throughout pregnancy, starting as early as ten weeks gestation. Results are
generally received within ten days (Vanstone et. al., 2014), opening the window to earlier
diagnostic testing (CVS).
Several clinical studies have been published assessing the use of NIPT for the detection of fetal
chromosomal conditions. The majority of these studies have focused on the detection of Down
syndrome among women with an increased chance of fetal chromosomal conditions. The
results of these studies have been consistent, reporting a DR rate reaching 100% and a FPR of
<1% (see Exhibit 2; Langois & Brock, 2013). Studies examining the effectiveness of NIPT for the
detection of other common fetal chromosomal conditions have also been carried out, with
similar results being reported for Trisomy 18 (see Exhibit 3; Langois & Brock, 2013). Overall,
2

With improved accuracy, specifically a reduced false positive rate, it is expected that fewer women will undergo
unnecessary invasive testing, which is associated with fetal loss.
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published results suggest NIPT to be a more accurate screening approach (than the current) for
common fetal aneuploidies in high-chance populations (Langois & Brock, 2013; Vanstone et. al.,
2014). Studies investigating the applicability of these results in average-chance populations are
currently underway (Vanstone et. al., 2014). The largest published study to date, with a cohort
of 2049 women, reported a DR of 100% and a FPR of <0.1% for Down syndrome and Trisomy
18 (Nicolaides, Syngelaki, Ashoor, Birdir, & Touzet, 2012). This suggests the test may be
universally appropriate.3
As with current screening approaches, although the chance is much lower, the chance of
receiving a false positive exists. Because of this, NIPT remains a screening tool and does not
replace invasive testing for diagnosis. Those who would consider termination based on a
diagnosis are still advised to undergo CVS or amniocentesis for confirmation (Langois & Brock,
2013). In certain situations, women may have to undergo a repeat test due to initial test failure.
This can happen in up to 6% of tests (Children’s Hospital of Eastern Ontario, 2014), often as a
result of poor quality control measures or low fetal fraction (less than 4% cffDNA in maternal
blood; Vanstone, et. al., 2014). Low fetal fraction may be a result of early gestation (fetal fraction
increases as gestational age increases) or maternal obesity. Other identified limitations of the
test include unclear results with multiple gestation pregnancies or chromosomal mosaicism.4
CURRENT INTEGRATION IN ONTARIO
In light of the evidence, the SOGC recommends NIPT be offered to women as a second tier
screening option (Langois & Brock, 2013). This means that NIPT should be offered to
individuals whose pregnancies have been identified as high-chance (on the basis of current
screening modalities) and who wish to continue testing, but avoid invasive testing. Similar
recommendations have come from other professional bodies, including the American College of
Obstetricians and Gynecologists (American Congress of Obstetricians and Gynecologists,
2012), the National Society of Genetic Counselors (National Society of Genetic Counselors,
2012), and the International Society of Prenatal Diagnosis (Children’s Hospital of Eastern
Ontario, 2014). Although NIPT is currently an available option to this population of women in
Canada, it is expensive, costing more than $800, and for the most part is only accessible to
those who can afford to pay for it (Okun et al., 2014).
In Ontario, the MOHLTC has recently begun supporting the use of NIPT in certain
circumstances. These circumstances are limited and are based on specific indications.5 Eligible
providers (genetics or maternal fetal medicine specialists) who believe their client meets the
criteria can submit an application for funding to the Ministry.6 Women who do not qualify for
NIPT funding and who wish to have the test must find a provider who is willing to facilitate the
process (with blood samples being sent to the U.S. for analysis) and pay out-of-pocket for the
service.
CURRENT CHALLENGES
Jenny Black, Maternal Fetal Medicine Specialist and chair of the PGSG, has experienced
applying to the MOHLTC on behalf of clients for funding of NIPT. Receiving variable responses
3

The majority of studies use the gold standard of comparing the detection rate of Down syndrome by NIPT with the
detection rate by diagnostic testing.
4 Mosaicism is a condition in which cells within an individual have a different genetic makeup.
5 Funding eligibility indications may include, in a singleton pregnancy, any one of the following: screen positive result,
women > 40 years of age at expected date of delivery, NT > 3.5 mm, pregnancy history or previous child with
aneuploidy. Other indications may include: anomalies identified on ultrasound and/or other risk factors (MOHLTC,
2014).
6 Approval from the ministry must be received prior to receiving the services (MOHLTC, 2014).
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from the MOHLTC and having few applications approved, Jenny has not been satisfied with the
current process. Discussing her challenges with colleagues, Jenny heard her frustrations being
echoed. Following the annual Ontario conference on new developments in prenatal genetics,
Jenny met with providers (midwives, family physicians, and genetic counselors) from across the
province to discuss their experience with NIPT. From the meeting, Jenny realized that confusion
regarding the appropriate use and funding of NIPT in Ontario was strong. Inconsistencies in
practice were common, with some providers offering the test to all clients (mainly out of liability
concern), while others were just learning of the new technology and had not been offering it at
all.
Jenny suspected that much of the confusion and variability in practice was attributable to the
rapid emergence of this new technology through the private market. Wanting to support the
ministry’s vision of a centralized, standardized, high quality screening program for Ontario
(Okun et al., 2014), Jenny knew changes to the current system would need to be made. She
also knew that the changes would need to be cost-effective, as resources were scarce within
the publicly funded system.
ECONOMIC EVALUATION7 OF NIPT INTEGRATION OPTIONS (OKUN et. al., 2014)
Different scenarios have been proposed for which the Ministry could introduce NIPT into the
public system. This includes NIPT as a second-tier contingency screen or NIPT as the primary
screen. These scenarios are compared to the current system, where NIPT remains mainly
within the private market. Three algorithms (see Exhibit 4) are presented, demonstrating the
screening pathway of each scenario. Numbers informing the algorithms and evaluation were
retrieved from the provincial Better Outcomes Registry Network (BORN) (fiscal year 2012-2013)
and the five Ontario regional laboratories. This includes data on test performance and cost,
number of total pregnancies, expected number of cases of Down syndrome, uptake of
screening and diagnostic testing, and pregnancy loss rate due to diagnostic testing (see
Exhibit 5).
Within each scenario the system performance and costs are analyzed (see Exhibit 6). The
performance outcomes analyzed include the total number of cases of Down syndrome detected,
the total number of invasive tests (amniocentesis) performed, and the total number of fetal
losses (false positive cases) related to invasive testing. The cost outcomes include the total cost
of the screening program (up to and including prenatal diagnosis of Down syndrome), the cost
per woman screened, and the cost per case of Down syndrome detected.
Overall assumptions within the evaluation include:
 Diagnostic testing may be directly offered to women identified as high-chance for fetal
chromosomal conditions;
 Diagnostic testing following primary screening is amniocentesis whereas NIPT is
accompanied with a first trimester ultrasound;
 Where contingent NIPT screening follows FTS as the primary screen8 it is assumed that
100% of those who receive a screen positive after FTS will undergo NIPT and 100% of
those who receive a positive result after NIPT will undergo amniocentesis; and
7

Information informing this section was retrieved from the economic evaluation conducted by Okun et. al., (2014).
This is a recent 2014 Ontario study, with its quality being validated within a critical appraisal by the Canadian Agency
for Drugs and Technologies in Health.
8 FTS is the only screening option that provides results within the first trimester. Using this screen as the primary
screen ensures NIPT (if warranted) can be performed within a reasonable time. FTS has a DR of up to 85% and FPR
of up to 9%. The high FPR is not of concern as screen positives will be screened with NIPT prior to diagnostic testing.
The lower DR however means that fewer cases of Down syndrome may be detected than if IPS were used.
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A provincial lead centre will be established to monitor and evaluate NIPT and therefore
an operating cost of $1,044,000 is added to the scenarios that include publicly funded
NIPT.

1. NIPT as a Commercial Test
NIPT would remain in the private market, with companies promoting its use directly to the
public and providers. Two different models were used to demonstrate this scenario (models
1-2 in Exhibit 6), with one using current FTS/IPS screening modalities and one using FTS as
the only screening modality. Based on the evaluation of these models, the total screening
costs to the system would range from $17,353,789-$17,580,080, with the cost per woman
screened being $179-$182, and the cost per case of Down syndrome diagnosed being
$112,919-$114,391. The performance of this scenario includes 3,211-4,247 invasive
procedures being performed, 154 cases of Down syndrome being detected, and 31-41
procedure-related fetal losses occurring.
2. NIPT as a Contingency Test (second-tier screening)
The use of NIPT as a contingent test would mean it is only offered to individuals based on
certain criteria. In this evaluation, NIPT is only offered to women who receive a screen
positive following FTS. Five different contingent NIPT models were created (models 4-8 in
Exhibit 6). These models depict possible alternatives and are based on the assumption that
as technology becomes safer and more accurate the rate of uptake will be higher, the
accuracy of FTS will improve with continued research and quality assurance, and the cost of
NIPT will decrease over time. Taking the different models into consideration, it is estimated
that the total cost of screening to the system will range from $17,353,081 to $21,372,742,
with the cost per woman screened being $179-$208, and the cost per case of Down
syndrome diagnosed being $68,530-$71,474. The performance of this scenario includes
293-1,358 invasive procedures being performed, 253-337 cases of Down syndrome being
detected, and 0-13 procedure-related fetal losses occurring.
3. NIPT as the Primary Testing Method
In this scenario (model 3 in Exhibit 6), NIPT would replace the current primary screening
options and would be offered to all pregnant women. This scenario is estimated to cost the
system a total of $85,146,250 with the cost per woman screened being $879, and the cost
per case of Down syndrome diagnosed being $286,428. The performance of this scenario
includes 394 invasive procedures being performed, 297 cases of Down syndrome being
detected, and 1 procedure-related fetal loss occurring.
RECOMMENDATION
Based on the evaluation, the introduction of NIPT into the public system would result in more
cases of Down syndrome being detected, fewer invasive tests being performed, and fewer
related pregnancy losses. However these benefits would come with an increased cost to the
healthcare system. NIPT as a primary test (which evidence does not yet fully support, but may
relatively soon) significantly increases the cost to the system, costing four to five times more
than the current system. NIPT as a contingency test is a more feasible option, costing slightly
more than the current system, yet deriving similar benefits to that of the primary approach.
Taking the economic evaluation into consideration, along with other relevant decision-making
elements, Jenny, together with the PGSG, needs to make recommendations to the MOHLTC for
an improved prenatal genetic screening program in Ontario.
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EXHIBIT 1
Current Prenatal Genetic Screening Options in Ontario
Down
syndrome
DR

Tests

Down
syndrome
FPR

Comments

Integrated Prenatal
Screening (IPS)
First Trimester (11-13+6/7
wks)
- Results available in 2nd trimester after blood
- NT – by registered
taken
sonographer
85-90%
2-4%
- maternal serum:
- Diagnostic test after counselling for screen
PAPP-A
positive = amniocentesis
Second Trimester (15+6/7
20
wks)
- maternal serum: AFP,
hCG, uE3
Serum Integrated
Prenatal Screening
- Results available in 2nd trimester after blood
(SIPS)
taken
First Trimester (11-13+6/7
wks)
- Diagnostic test after counselling for screen
- maternal serum:
80-90%
2-7%
positive = amniocentesis
PAPP-A
Second Trimester (15- Is available in most places where NT ultrasound
20+6/7 wks)
is not available
- maternal serum: AFP,
hCG, uE3, DIA
(*) First Trimester
Combined Screening
- Results available in 1st trimester after blood
(FTS)
taken – usually end of 1st trimester, earliest results
First Trimester (11-13+6/7
wks)
78-85%
3-9%
- CVS for diagnostic testing
- NT – by registered
sonographer
- Does not screen for NTD*
- maternal serum:
PAPP-A, ƒbhCG
(*) First trimester screening is not available in all areas of Ontario
* NTDs (open neural tube defects) can be screened for by MS-AFP and/or ultrasound at 18-20 weeks
DR: detection rate – also known as sensitivity, is the probability that a fetus affected with Down syndrome will be
detected by the prenatal test
FPR: false positive rate – the proportion of women with unaffected pregnancies who have positive results
: increased value
: decreased value
Test
Maternal Serum Screen (Quadruple
Screening – MSS)
Second Trimester (15-20+6/7 wks)
- maternal serum: AFP, hCG, uE3,
DIA
Source:

Down
syndrome DR

Down syndrome
FPR

75-85%

5-10%

Prenatal Screening Ontario, 2014b.
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EXHIBIT 2
Published Studies Examining the Use of NIPT for the Detection of Down Syndrome
Table 2. Results of validation studies for non-invasive detection of fetal trisomy 21
Number
samples tested
764
232
1696

Failure rate*
1.4%
N/A
0.8%

Sequencing
approach
8-plex shotgun
2-plex shotgun
4-plex shotgun

467

3.9%

4-plex shotgun

Lau et al. 201111
Sehnert et al. 201212
Sparks et al. 201213
Ashoor et al. 201214
Bianchi et al. 201215

108
47
167
400
532

0
0
0†
0.75%
3%

12-plex shotgun
1-plex shotgun
96-plex selective
96-plex selective
6-plex

Norton et al. 201216

3228

4.5%

96-plex selective

Study
Chiu et al. 20118
Palomaki et al.
20119
Ehrich et al. 201110

Detection
rate
79.1% (68/86)
100% (86/86)
98.6% (209/212)
95% Cl 95.9 to 99.7
100% (39/39)
95% Cl 89 to 100
100% (11/11)
100% (13/13)
100% (36/36)
100% (50/50)
100% (89/89)
95% Cl 95.9 to 100
100% (81/81)
95% Cl 95.5 to 100

Falsepositive rate
1.1%
2.1%
0.2%
95% Cl <0.1 to 0.6
0.2%
95% Cl 0.1 to 1.5
0
0
0.8%
0
0
0.03%
35% Cl 0.002 to 0.2

*Percentage of samples that did not meet quality control requirements for the sequencing so that no results could be obtained.
†5% failure in their training set.
N/A: not applicable – only samples that passed original sequencing quality control were retested within the 2-plex.

Source:

Langois & Brock, 2013 (by permission of The Society of Obstetricians and Gynaecologists of Canada).
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EXHIBIT 3
Published Studies Examining the Use of NIPT for the Detection of Trisomy 18
Table 3. Results of validation studies for non-invasive detection of fetal trisomy
Study
Lau et al. 201111
Sehnert et al. 201212
Sparks et al. 201213
Ashoor et al. 201214
Bianchi et al. 201215
Norton et al. 201215
Palomaki et al. 201215
Source:

Sequencing
approach
12-plex shotgun
1-plex shotgun
96-plex selective
96-plex selective
6-plex
96-plex selective
4-plex shotgun

Trisomy 18
detection rate
90% (9/10)
100% (8/8)
100% (8/8)
98% (49/50)
97.2% (35/36)
97.4% (37/38)
100% (59/59)

Trisomy 18
false-positive rate
0
0
0.8%
0
0
0.07%
0.28%

Langois & Brock, 2013 (by permission of The Society of Obstetricians and Gynaecologists of Canada).
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EXHIBIT 4
Algorithms of Screening Pathways

1. Current model
No Screening
Pregnancies in
Ontario

Diagnostic
Testing

Screen Positive
Screening
(FTS/IPS)

Screen Negative

Diagnostic
Testing

2. Contingent model
No Screening
Pregnancies in
Ontario

Screen Positive

FTS
Diagnostic
Testing

NIPT

Screen Positive
Screen Negative

Screen Negative
Diagnostic
Testing

3. Primary model
No Screening
Pregnancies in
Ontario

NIPT
Diagnostic
Testing

Screen Positive
Screen Negative

Source: Adapted from Okun et. al., 2014.
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EXHIBIT 5
Evaluation Assumptions
Table 1 Background conditions and assumptions for various scenarios of prenatal screening for Down
syndrome in Ontario
Contingent cffDNA

Conditions/
assumptions
# total pregnancies
Expected number of cases
of DS
Uptake of prenatal
screening
Number of screened
pregnancies
Detection rate of IPS/FTS
Positive rate
Rate of diagnostic testing
among screen-positive
women
Rate of diagnostic testing
among screen-negative or
no screening group
Pregnancy loss rate due to
amniocentesis (ref RCT)
Cost of cffDNA test (ref)

Current
system, No
cffDNA (1)
144 570

FTS,
No
cffDNA
(2)
144 570

Primary
cffDNA DS
screen (3)
144 570

Current FTS
performance
(4)
144 570

Cost
recovery
(5)
144 570

Improved
DR (6)
144 570

Higher
uptake (7)
144 570

Optimized
FTS (8)
144 570

448

448

448

448

448

448

448

448

67%

67%

67%

67%

67%

67%

80%

80%

96 862

96 862

96 862

96 862

96 862

96 862

115 656

115 656

85%
3.6%

85%
5.4%

99%
0.1%

85%
5.4%

85%
5.4%

95%
11.2%

85%
5.4%

95%
11.2%

60%

60%

100%

100%

100%

100%

100%

100%

1.2%

1.2%

0%

1.2%

1.2%

0%

1.2%

0%

1%

1%

1%

1%

1%

1%

1%

1%

__

__

$795

$795

$744

$795

$795

$600

cffDNA, cell-free fetal DNA; FTS, first trimester screening; DS, Down syndrome; DR, detection rate; IPS, integrated prenatal screening.

Source:

Okun et. al., 2014 (by permission of John Wiley and Sons and Copyright Clearance Center).
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EXHIBIT 6
Evaluation Outcomes: Models 1-3
Table 2 Performance and cost outcomes with different modeled
scenarios of prenatal screening for Down syndrome in Ontario

Outcomes
# amniocentesis
performed
# prenatal cases of DS
detected prenatally
# amniocenteses related
losses of non-DS
affected pregnancies
Total program cost
Cost/woman screened
Cost/prenatally
diagnosed pregnancy
with DS
Cost/additional
prenatally diagnosed
pregnancy with DS

Current
system, No
cffDNA (1)

FTS, No
cffDNA (2)

Primary
cffDNA DS
screen (3)a

3211b

4247b

394c

154

154

297

31

41

1

$17 353 789
$179

$17 580 080
$182

$85 146 250
$879

$112 919

$114 391

$286 428

__

__

$472 139

cffDNA, cell-free DNA; FTS, first trimester screening; DS, Down syndrome.
a
Includes cost of first trimester ultrasound.
b
Assumes 1.2% of screen-negative women continue to request amniocentesis.
c
Assumes only contingent screen-positive women undergo amniocentesis

Source:

Okun et. al., 2014 (by permission of John Wiley and Sons and Copyright Clearance Center).
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EXHIBIT 7
Evaluation Outcomes: Models 4-8
Table 3 Performance and cost outcomes with different cell-free fetal DNA contingent modeled scenarios

Outcomes

# amniocentesis performed
# prenatal cases of DS
detected prenatally
# amniocenteses related
losses of non-DS affected
pregnancies
Total program cost
Cost/woman screened
Cost/prenatally diagnosed
pregnancy with DS
Cost/additional prenatally
diagnosed pregnancy with
DS

Contingent cffDNA with
current FTS performance
(4)

Contingent cffDNA
with Cost recovery
(5)

Contingent cffDNA
with Improved DR
(6)

Contingent cffDNA
with Higher uptake
(7)

Contingent cffDNA
with Optimized FTS
(8)

1358a
253

1358a
253

293b
282

1621a
302

350b
337

11

11

0

13

0

$17 619 839
$182
$69 583

$17 353 081
$179
$68 530

$20 184 795
$208
$71 474

$20 836 046
$180
$68 913

$21 372 742
$185
$63 383

$2673

$0

$21 933

$23 423

$21 900

cffDNA, cell-free DNA; FTS, first trimester screening; DS, Down syndrome.
a

Assumes 1.2% of screen-negative women continue to request amniocentesis.

b

Assumes only contingent screen-positive women undergo amniocentesis.

Source:

Okun et. al., 2014 (by permission of John Wiley and Sons and Copyright Clearance Center).
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BACKGROUND
Since 1993, the Ontario Ministry of Health and Long-Term Care (MOHLTC) has financed
prenatal genetic screening through its provincial health insurance plan. In 2013, a new
technology became available. Non-invasive prenatal testing (NIPT) promises improved
accuracy and screening safety at a higher cost than other screening tests. Since 2013, pregnant
women in Ontario have been paying for the test themselves. In March 2014, the Ministry
appointed a Prenatal Genetic Screening Group (PGSG), to make recommendations on making
NIPT available through the provincial health insurance plan. The Ministry requested an
economic evaluation, appraising the value of NIPT.
OBJECTIVES
1. Understand the role of economic evaluation in health policy decision-making
2. Critically appraise the quality of an economic evaluation and evaluate its applicability
3. Interpret economic evaluations and use the results to inform policy recommendations
4. Discuss the challenges of interpreting cost-effectiveness analysis as compared to cost-utility
analysis
5. Consider broader social, political, and ethical concerns such as equity, quality assurance,
allocative efficiency, and appropriate use of screening in making health policy decisions
DISCUSSION QUESTIONS
1. How should scarce resources be allocated within a publically funded healthcare system?
2. What type of economic evaluation was performed (cost-minimization, cost-effectiveness,
cost-utility, cost-benefit)?
3. How would you appraise the quality of the economic evaluation? Is it adequate for use in
policy decision-making?
4. What are the challenges associated with using the cost per case of Down syndrome
diagnosed as a measure of value for money? Are there additional analyses you would
recommend?
5. What recommendations would you make about NIPT screening based on the results of
economic evaluation?
6. Are there important factors not addressed by the economic evaluation?
7. Should the ministry allocate resources to supporting parents of children with Down
syndrome?
KEYWORDS
Economic evaluation; cost-effectiveness analysis; genetic screening; Down syndrome.
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